Polycystic Ovarian Syndrome
Conditions
Interventions
Two groups:Rosiglitazone 4mg B.D. (8mg per day) 12 months versus Placebo 1 tab B.D.
Sponsors
None listed
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: INCLUSION CRITERIA: (At least 2 of the major criteria listed below) Major criteria: 1. Anovulation (with other causes of anovulation excluded); 2) Clinical signs of hyperandrogenism (hirsutism or acne) and/or hyperandrogenemia (with other causes of hyperandrogenemia excluded); Minor criteria: 1) Elevated early follicular phase (LH >10 IU/L); 2. Elevated LH/FSH ratio >2.5); 3. Polycystic ovaries on ultrasound scan; 4. Obesity (BMI > 25) / Insulin resistance.
Exclusion criteria
Exclusion criteria: EXCLUSION CRITERIA: 1. Women with PCOS who are planning for pregnancy, or undergoing fertility treatment; 2. Women with PCOS who are already on oral hypoglycaemic agents or insulin treatment; 3. Women with cardiovascular disease, hepatic or renal function impairment; 4. Women on corticosteroid therapy; 5. Women with known endometrial hyperplasia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstrual status; hirsutism score, free testosterone, SHBG level; | — |
Secondary
| Measure | Time frame |
|---|---|
| IMT (Intima Madia Thickness); | — |
Countries
China
Contacts
Public ContactProf. Tam Wing Hung
Outcome results
None listed